Abstract:To effectively incorporate in vitro-in silico-based methods into the regulation of consumer product safety, a quantitative connection between product phthalate concentrations and in vitro bioactivity data must be established for the general population. We developed, evaluated, and demonstrated a modeling framework that integrates exposure and pharmacokinetic models to convert product phthalate concentrations into population-scale risks for phthalates and their substitutes. A probabilistic exposure model was developed to generate the distribution of multi-route exposures based on product phthalate concentrations, chemical properties, and human activities. Pharmacokinetic models were developed to simulate population toxicokinetics using Bayesian analysis via the Markov chain Monte Carlo method. Both exposure and pharmacokinetic models demonstrated good predictive capability when compared with worldwide studies. The distributions of exposures and pharmacokinetics were integrated to predict the population distributions of internal dosimetry. The predicted distributions showed reasonable agreement with the U.S. biomonitoring surveys of urinary metabolites. The "source-tooutcome" local sensitivity analysis revealed that food contact materials had the greatest impact on body burden for di(2-ethylhexyl) adipate (DEHA), di-2-ethylhexyl phthalate (DEHP), di(isononyl) cyclohexane-1,2dicarboxylate (DINCH), and di(2-propylheptyl) phthalate (DPHP), whereas the body burden of diethyl phthalate (DEP) was most sensitive to the concentration in personal care products. The upper bounds of predicted plasma concentrations showed no overlap with ToxCast in vitro bioactivity values. Compared with the in vitro-toin vivo extrapolation (IVIVE) approach, the integrated modeling framework has significant advantages in mapping product phthalate concentrations to multi-route risks, and thus is of great significance for regulatory use with a relatively low input requirement. Further integration with new approach methodologies will facilitate these in vitro-in silico-based risk assessments for a broad range of products containing an equally broad range of chemicals.

Human health risk assessment of 6:2 Cl-PFESA through quantitative in vitro to in vivo extrapolation by integrating cell-based assays, an epigenetic key event, and physiologically based pharmacokinetic modeling

Development of Physiologically Based Toxicokinetic Models for 3-Monochloropropane-1,2-diol and Glycidol.

Hazard and Risk Characterization of 56 Structurally Diverse PFAS Using a Targeted Battery of Broad Coverage Assays Using Six Human Cell Types.

Assessment of Endocrine-Disrupting Effects of Emerging Polyhalogenated Carbazoles (phczs): in Vitro, in Silico, and in Vivo Evidence

An Integrated Exposure and Pharmacokinetic Modeling Framework for Assessing Population-Scale Risks of Phthalates and Their Substitutes

Hazard and Risk Characterization and Grouping of 56 Structurally Diverse PFAS Using a Targeted Battery of Broad Coverage Assays in Six Human Cell Types

A novel procedure for predicting chronic toxicities and ecological risks of perfluorinated compounds in aquatic environment

Tissue accumulation and hepatotoxicity of 8:2 chlorinated polyfluoroalkyl ether sulfonate: A multi-omics analysis deciphering hepatic amino acid metabolic dysregulation in mice

Health Risk Assessment of Perfluorooctane Sulfonate and Perfluorooctanoic Acid Exposure in China Based on Epidemiological Data

An in vitro-in silico workflow for predicting renal clearance of PFAS

Lipid Metabolism Disorders Effects of 6:2 Chlorinated Polyfluorinated Ether Sulfonate Through Hsa-miRNA-532–3p/Acyl-CoA Oxidase 1(ACOX1) Pathway

A new method to quantify the health risks from sources of perfluoroalkyl substances, combined with positive matrix factorization and risk assessment models.

Subchronic Reproductive Effects of 6:2 Chlorinated Polyfluorinated Ether Sulfonate (6:2 Cl-PFAES), an Alternative to PFOS, on Adult Male Mice.

In Vitro Hepatic Clearance Evaluations of Per- and Polyfluoroalkyl Substances (PFAS) across Multiple Structural Categories

Human exposure to F-53B in China and the evaluation of its potential toxicity: An overview

Fish Physiologically Based Toxicokinetic Modeling Approach for In Vitro-In Vivo and Cross-Species Extrapolation of Endocrine-Disrupting Chemicals in Risk Assessment

Characterizing PFAS hazards and risks: a human population-based in vitro cardiotoxicity assessment strategy

Prediction of HC 5 s for phthalate esters by use of the QSAR–ICE model and ecological risk assessment in Chinese surface waters

Integrating Physiologically Based Pharmacokinetic Modeling-Based Forward Dosimetry and in Vitro Bioassays to Improve the Risk Assessment of Organophosphate Esters on Human Health

In vitro screening of understudied PFAS with a focus on lipid metabolism disruption

Deriving aquatic PNECs of endocrine disruption effects for PFOS and PFOA by combining species sensitivity weighted distributions and adverse outcome pathway networks